Next Article in Journal
A Hearty Dose of Noncoding RNAs: The Imprinted DLK1-DIO3 Locus in Cardiac Development and Disease
Next Article in Special Issue
Potential Impact of COMT-rs4680 G > A Gene Polymorphism in Coronary Artery Disease
Previous Article in Journal / Special Issue
Oxidized Low-Density Lipoprotein Serum Concentrations and Cardiovascular Morbidity in End Stage of Renal Disease
Article Menu

Export Article

Open AccessReview
J. Cardiovasc. Dev. Dis. 2018, 5(3), 36;

ApoB-100 Lipoprotein Complex Formation with Intima Proteoglycans as a Cause of Atherosclerosis and Its Possible Ex Vivo Evaluation as a Disease Biomarker

Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, 141 86 Stockholm, Sweden
Translational Sciences, Cardiovascular, Renal and Metabolism, IMED Biotech Unit, AstraZeneca, 431 83 Gothenburg, Sweden
Author to whom correspondence should be addressed.
Received: 14 June 2018 / Revised: 27 June 2018 / Accepted: 28 June 2018 / Published: 1 July 2018
(This article belongs to the Special Issue Lipoprotein Metabolism and Atherosclerosis)
Full-Text   |   PDF [583 KB, uploaded 1 July 2018]   |  


Experimental and clinical data indicate that the initiation and progress of atherosclerosis and its clinical manifestations are first caused by circulating apoB-100 lipoproteins that enter and are retained in the arterial intima. Extracellular sulfated proteoglycans (PGs) of the intima are the retention agents. The PGs also initiate physical and biochemical lipoprotein degradation with the production of bioactive, lipid products that trigger an inflammatory response that leads to atherosclerosis. There are many simple methods for measuring abnormalities of circulating lipoproteins and their relation to atherosclerotic cardiovascular disease (ACVD). However, limited research aims to evaluate procedures that could report quantitatively about the contribution of the interaction of apoB-100 lipoprotein-arterial intima PGs to clinical manifestation of ACVD. In the present review we discuss observations indicating that simple ex vivo evaluation of the affinity of apoB-100 lipoproteins for arterial PGs and glycosaminoglycans (GAGs) can give an indication of its association with clinical manifestations of atherosclerosis. In addition, we discuss molecular and cellular aspects of the apoB-100 lipoproteins association with arterial PGs that are related to atherogenesis and that support the experimental framework behind the current “Response-to-Retention” hypothesis of atherosclerosis. View Full-Text
Keywords: apoB-100 lipoproteins; proteoglycans; interaction; atherosclerosis apoB-100 lipoproteins; proteoglycans; interaction; atherosclerosis

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hurt-Camejo, E.; Camejo, G. ApoB-100 Lipoprotein Complex Formation with Intima Proteoglycans as a Cause of Atherosclerosis and Its Possible Ex Vivo Evaluation as a Disease Biomarker. J. Cardiovasc. Dev. Dis. 2018, 5, 36.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Cardiovasc. Dev. Dis. EISSN 2308-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top